Premier Biomedical,
a research-based company focused on developing medical treatments for a range
of neurological diseases and more, reports that in collaboration with the
University of Texas at El Paso it has conducted a study further confirming the
ability of its breast cancer therapy over standard chemotherapy in mice.
Results demonstrate
that mice on this regimen had a distinctively higher survival rate, smaller
tumor volume, and maintained weight, as opposed to losing body mass as was
demonstrated by control subjects on standard chemotherapy.
Notably, no mouse
treated with Premier Biomedical’s treatment regimen developed metastatic
disease, a drastic achievement compared to mice administered traditional
therapies in the company’s study, 20 percent of which suffered metastases to
the lungs.
According to Premier
Biomedical, the tumor burden of metastatic lesions causing systemic wasting of
body mass is the leading cause of death in patients with breast cancer. The
results of the company’s study may demonstrate the efficacy of Premier
Biomedical’s breast cancer candidate regimen as an immune-system-modulating
therapy precluding metastatic complications.
Full details of the
study are being submitted for peer review to the journal of Molecular Cancer
Therapeutics in the coming weeks. That report will delve into methodologies and
validate the statistical significance of results. It will also highlight a
subset of our study in which pre-existing breast cancer was not only completely
eradicated in mice after they received Premier’s treatment, but subsequent
attempts to inject new tumor cells into those mice failed to cause cancer
because their immune system was apparently primed to reject it.
“This confirmation
of results is a positive indication of Premier Biomedical’s ability to bring
desperately needed therapy to patients in need. If our breast cancer treatment
regimen can successfully prevent metastasis in human patients as it has in
mice, then the impact of our therapy on survival rates would be profoundly
significant,” William A. Hartman, president and CEO of Premier Biomedical
stated in the news release. “Furthermore, our tests verify that we may not only
have developed an effective therapy against pre-existing breast cancer, but may
also have discovered an effective means of preventing breast cancer recurrence
that needs more targeted development. This may be an industry first against the
threat of breast cancer.”
Hartman added that
results of the most recent study support the company’s intention to apply for a
Section 902 ‘Breakthrough Therapy’ fast track designation from the FDA upon
completion of preliminary clinical trials in humans.
Results from Premier
Biomedical’s now-duplicated breast cancer study has previously been authored
and published by The University of Texas at El Paso:
http://newsuc.utep.edu/index.php/research-news/1068-eliminating-disease-research-partnership-shows-promise.
For more
information, visit www.premierbiomedicalinc.com
About QualityStocks
QualityStocks is committed to connecting
subscribers with companies that have huge potential to succeed in the short and
long-term future. We offer several ways for investors to find, evaluate, and
learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment